IgD multiple myeloma: Clinical, biological features and prognostic value of the serum free light chain assay. Djidjik R et al. Pathol Biol (Paris). 2015 Aug 17. pii: S0369-8114(15)00057-7. doi: 10.1016/j.patbio.2015.06.002. [Epub ahead of print]. Patient dose evaluation for the whole-body low-dose multidetector CT (WBLDMDCT) skeleton study in multiple myeloma (MM). Cretti F et al. Radiol Med. 2015 Aug 19. [Epub ahead of print]. Clinical…
Lenalidomide is safe and active in waldenström macroglobulinemia. Fouquet G et al. Am J Hematol. 2015 Aug 18. doi: 10.1002/ajh.24175. [Epub ahead of print]. Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine. Simeon V et al. Int J Mol Sci. 2015 Jul 30;16(8):17514-34. doi: 10.3390/ijms160817514. Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and…
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. Lokhorst HM et al. N Engl J Med. 2015 Aug 26. [Epub ahead of print]. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Kumar SK et al. Blood Cancer J. 2015 Aug 14;4:e338. doi: 10.1038/bcj.2015.60. Panobinostat: the small molecule metalloenzyme inhibitor with marvelous anticancer activity. Ganai SA. Curr Top Med…
A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias. Lionetti M et al. Oncotarget. 2015 Jul 20. [Epub ahead of print]. The natural compound forskolin synergizes with dexamethasone to induce cell death in myeloma cells via BIM. Follin-Arbelet V et al. Sci Rep. 2015 Aug 26;5:13001. doi: 10.1038/srep13001. Notch signaling deregulation in multiple myeloma: A rational molecular target. Colombo M et…
Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury.
Yadav P et al. Eur J Haematol. 2015 Aug 6. doi: 10.1111/ejh.12644. [Epub ahead of print].
Re-invigorating rather than re-inventing the wheel: augmenting the impact of salvage autologous stem cell transplantation for multiple myeloma in the era of novel agents. Cook G. Bone Marrow Transplant. 2015 Aug 3. doi: 10.1038/bmt.2015.175. [Epub ahead of print]. IgG Lambda Myeloma Presenting as Plasmacytic Ascites: Case Report and Review of Literature. Mitra S et al. Indian J Hematol Blood Transfus. 2015 Dec;31(4):472-9. doi: 10.1007/s12288-014-0454-5.…
Rapid evolving into acute myeloid leukemia in a patient with multiple myeloma and concurrent myelodysplasia after VTD therapy. Gu ZH et al. Int J Clin Exp Med. 2015 Jun 15;8(6):10105-10108. Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma. Vincent L et al. Blood Cancer J. 2015 Aug 21;5:e341. doi: 10.1038/bcj.2015.48. Hematopoietic cell transplantation in patients with medication-related osteonecrosis of the jaws. Mawardi…
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. Palumbo A et al. J Clin Oncol. 2015 Aug 17. pii: JCO.2014.60.2466. [Epub ahead of print]. Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myelomapatients aged 65 years or older: a retrospective single Institutional analysis. Minoia C et al. Bone Marrow Transplant. 2015 Aug…